Skip to main content
Gan & Lee Pharmaceuticals. logo

Gan & Lee Pharmaceuticals. — Investor Relations & Filings

Ticker · 603087 ISIN · CNE100003ZH1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2026-05-24 Notice of Dividend Amou…
Country CN China
Listing Shanghai Stock Exchange 603087

About Gan & Lee Pharmaceuticals.

https://www.ganlee.com/

Gan & Lee Pharmaceuticals is a biopharmaceutical company specializing in the research, development, production, and commercialization of insulin analogs and medical devices. The company focuses on diabetes care, offering a comprehensive portfolio that includes insulin glargine, insulin lispro, and insulin aspart, alongside delivery systems such as reusable and disposable insulin pens. Beyond its core expertise in metabolic disorders, the firm is expanding its research pipeline into oncology, cardiovascular diseases, and autoimmune conditions. Utilizing advanced recombinant DNA technology, the company maintains vertically integrated manufacturing capabilities to ensure high-quality therapeutic solutions. Its products are distributed across global markets, aiming to improve the quality of life for patients requiring long-term endocrine management.

Recent filings

Filing Released Lang Actions
2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 92% confidence The document is an official announcement detailing the company’s 2025 fiscal year cash dividend distribution plan, including dividend per share, record dates, ex‐dividend dates, payment dates, tax treatment, and implementation procedures. This matches the definition of a Notice of Dividend Amount (DIV). It is not a full financial report or report publication notice, but a standalone dividend announcement.
2026-05-24 Chinese
关于赖脯胰岛素注射液获得欧盟委员会上市许可的公告
Regulatory Filings Classification · 85% confidence The document is an official securities announcement by 甘李药业’s board, disclosing that its insulin product received EU marketing authorization. It contains no financial statements or management discussion, nor is it an AGM, earnings release, or capital transaction. This is a general regulatory/compliance announcement, fitting our fallback category for miscellaneous regulatory filings.
2026-05-14 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is the official announcement of resolutions passed at the 2025 annual general meeting, detailing meeting attendance and voting results for each agenda item. This matches the Definition for Declaration of Voting Results & Voting Rights Announcements (Code: DVA), as it provides detailed shareholder vote outcomes.
2026-05-13 Chinese
关于门冬胰岛素注射液获得欧盟委员会上市许可的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from 甘李药业股份有限公司 regarding the approval of their product 门冬胰岛素注射液 by the European Commission for market authorization in the EU and related regions. It includes product details, market context, and risk warnings. The document is short (1145 characters) and serves as a regulatory announcement about a product approval, not a financial report or detailed investor presentation. It does not contain financial statements, management discussion, or detailed financial data. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about product approval and market authorization.
2026-05-06 Chinese
战略委员会工作细则（2026年4月）
Governance Information Classification · 95% confidence The document is the internal ‘Work Rules’ for the Board’s Strategic Committee of 甘李药业股份有限公司, detailing the committee’s composition, responsibilities, meeting procedures, decision-making processes, and governance structure. This is an internal governance charter rather than a financial report or announcement. It therefore falls under Governance Information (CGR).
2026-04-22 Chinese
2025年度董事会工作报告
Management Reports Classification · 88% confidence The document is the 2025 Annual Work Report of the Board of Directors of 甘李药业股份有限公司, summarizing the company’s operational performance, R&D, strategy, governance and board activities. It is not a full statutory annual report, not an earnings release or proxy statement, nor an announcement of board changes. It provides detailed management discussion and analysis of financial results and outlook. Therefore it best fits the “Management Reports (MDA)” category.
2026-04-22 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.